{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T19:08:31Z","timestamp":1792609711376,"version":"4.5.0"},"reference-count":57,"publisher":"The Endocrine Society","issue":"10","license":[{"start":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T00:00:00Z","timestamp":1781740800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000780","name":"European Union","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100020278","name":"EU","doi-asserted-by":"publisher","award":["FIS 22\/01364"],"award-info":[{"award-number":["FIS 22\/01364"]}],"id":[{"id":"10.13039\/501100020278","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Instituto Carlos III"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,9,16]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Acromegaly is a heterogeneous disease in which delayed biochemical control remains common despite the availability of multiple therapeutic options. Traditional stepwise medical treatment algorithms often rely on the use of first-generation somatostatin receptor ligands (fgSRLs) as first-line drugs with empirical escalation and trial-and-error approaches, prolonging patients' exposure to hormonal excess.<\/jats:p>\n                  <jats:p>Cluster analyses indicate that overall, 3 main classes of patients with acromegaly representing distinct biological phenotypes can be recognized: (1) young patients with invasive macroadenomas and frequent resistance to fgSRLs; (2) older patients with noninvasive tumors and SRL responsiveness in the majority of them; and (3) patients with intermediate features often requiring combination medical therapy in whom prediction of response is more challenging.<\/jats:p>\n                  <jats:p>From a practical perspective, biomarker-guided treatment selection based on T2-weighted magnetic resonance imaging signal intensity, the short acute octreotide test, and tumor immunohistochemistry, following the strategy validated in the ACROFAST study, is applicable in clinical practice. It allows prompt biochemical control and tumor volume reduction, a rationale leading to superior effectiveness performance than the classic sequencing therapy involving the universal utilization of fgSRLs as first option.<\/jats:p>\n                  <jats:p>In the era of integrative and participative medicine, such a protocol enables the early identification of most patients unlikely to respond to fgSRLs, thus supporting timely initiation of pegvisomant, pasireotide, or combination therapy, and the achievement of hormonal control in nearly 80% of patients.<\/jats:p>\n                  <jats:p>Conclusion Precision medicine has become a practical reality in acromegaly. A biomarker-guided strategy improves therapeutic efficiency and should be incorporated into contemporary clinical practice.<\/jats:p>","DOI":"10.1210\/clinem\/dgag241","type":"journal-article","created":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T11:18:49Z","timestamp":1781695129000},"page":"2969-2983","source":"Crossref","is-referenced-by-count":1,"title":["Approach to the patient: precision medicine\u2013guided evaluation and treatment of acromegaly"],"prefix":"10.1210","volume":"111","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6744-7195","authenticated-orcid":false,"given":"Manel","family":"Puig-Domingo","sequence":"first","affiliation":[{"name":"Endocrinology and Nutrition Service, Hospital Universitari Germans Trias i Pujol , Badalona 08916 ,","place":["Spain"]},{"name":"Endocrine Tumors Research Group, Germans Trias i Pujol Research Institute , Badalona 08916 ,","place":["Spain"]},{"name":"Department of Medicine, Universitat Aut\u00f2noma de Barcelona , Campus de can Ruti, Badalona 08916 ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Montserrat","family":"Marques-Pamies","sequence":"additional","affiliation":[{"name":"Endocrine Tumors Research Group, Germans Trias i Pujol Research Institute , Badalona 08916 ,","place":["Spain"]},{"name":"Endocrinology and Nutrition Service, Hospital de Granollers , Granollers 08402 ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel","family":"Sampedro","sequence":"additional","affiliation":[{"name":"Endocrinology and Nutrition Service, Hospital Universitario la Princesa , Madrid 28006 ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1030-9119","authenticated-orcid":false,"given":"Joan","family":"Gil","sequence":"additional","affiliation":[{"name":"Endocrine Tumors Research Group, Germans Trias i Pujol Research Institute , Badalona 08916 ,","place":["Spain"]},{"name":"CIBERER Group 747, Instituto de Salud Carlos III , Madrid 28029 ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0519-0072","authenticated-orcid":false,"given":"Marta","family":"Araujo-Castro","sequence":"additional","affiliation":[{"name":"Endocrinology and Nutrition Service, Hospital Universitario Ram\u00f3n y Cajal , Madrid 28034 ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebeca","family":"Mart\u00ednez-Hern\u00e1ndez","sequence":"additional","affiliation":[{"name":"Endocrinology and Nutrition Service, Hospital Universitario la Princesa , Madrid 28006 ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8837-4343","authenticated-orcid":false,"given":"Betina","family":"Biagetti","sequence":"additional","affiliation":[{"name":"Endocrinology and Nutrition Service, Hospital Universitari Vall D\u2019Hebron , Barcelona 08035 ,","place":["Spain"]},{"name":"Endocrine Research Group, Vall D\u2019Hebron Research Institute , Barcelona 08035 ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mireia","family":"Jord\u00e0","sequence":"additional","affiliation":[{"name":"Endocrine Tumors Research Group, Germans Trias i Pujol Research Institute , Badalona 08916 ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3864-0105","authenticated-orcid":false,"given":"Elena","family":"Valassi","sequence":"additional","affiliation":[{"name":"Endocrinology and Nutrition Service, Hospital Universitari Germans Trias i Pujol , Badalona 08916 ,","place":["Spain"]},{"name":"Endocrine Tumors Research Group, Germans Trias i Pujol Research Institute , Badalona 08916 ,","place":["Spain"]},{"name":"CIBERER Group 747, Instituto de Salud Carlos III , Madrid 28029 ,","place":["Spain"]},{"name":"Department of Medicine, Universitat Internacional de Catalunya , Barcelona 08017 ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M\u00f3nica","family":"Marazuela","sequence":"additional","affiliation":[{"name":"Endocrinology and Nutrition Service, Hospital Universitario la Princesa , Madrid 28006 ,","place":["Spain"]},{"name":"Instituto de Investigaci\u00f3n Sanitaria la Princesa , Madrid 28006 ,","place":["Spain"]},{"name":"Department of Medicine, Universidad Aut\u00f3noma de Madrid , Madrid 28029 ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2026,6,18]]},"reference":[{"issue":"19","key":"2026091519582375800_dgag241-B1","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.1056\/NEJMra2409076","article-title":"Acromegaly","volume":"393","author":"Giustina","year":"2025","journal-title":"N Engl J Med"},{"issue":"2","key":"2026091519582375800_dgag241-B2","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1210\/jc.2003-031199","article-title":"Factors influencing mortality in acromegaly","volume":"89","author":"Holdaway","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"issue":"11","key":"2026091519582375800_dgag241-B3","doi-asserted-by":"crossref","first-page":"3933","DOI":"10.1210\/jc.2014-2700","article-title":"Acromegaly: an endocrine society clinical practice guideline","volume":"99","author":"Katznelson","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"issue":"9","key":"2026091519582375800_dgag241-B4","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.1210\/clinem\/dgad141","article-title":"Mortality in acromegaly diagnosed in older individuals in Spain is higher in women compared to the general Spanish population","volume":"108","author":"Biagetti","year":"2023","journal-title":"J Clin Endocrinol Metab"},{"issue":"11","key":"2026091519582375800_dgag241-B5","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1038\/s41574-025-01148-2","article-title":"Consensus on acromegaly therapeutic outcomes: an update","volume":"21","author":"Melmed","year":"2025","journal-title":"Nat Rev Endocrinol"},{"issue":"10","key":"2026091519582375800_dgag241-B6","doi-asserted-by":"crossref","DOI":"10.1210\/jendso\/bvad104","article-title":"Treatment patterns, adherence, persistence, and health care resource utilization in acromegaly: a real-world analysis","volume":"7","author":"Fleseriu","year":"2023","journal-title":"J Endocr Soc"},{"issue":"6","key":"2026091519582375800_dgag241-B7","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1210\/clinem\/dgac037","article-title":"Approach to the patient with treatment-resistant acromegaly","volume":"107","author":"Coopmans","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2026091519582375800_dgag241-B8","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1186\/s41687-025-00965-3","article-title":"Real-world burden of disease, treatment, and healthcare resource utilization in acromegaly: a quantitative survey of patient experiences","volume":"9","author":"Koobatian","year":"2025","journal-title":"J Patient Rep Outcomes"},{"key":"2026091519582375800_dgag241-B9","doi-asserted-by":"crossref","first-page":"1068061","DOI":"10.3389\/fendo.2022.1068061","article-title":"Molecular targets in acromegaly","volume":"13","author":"Labadzhyan","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"6","key":"2026091519582375800_dgag241-B10","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1530\/ERC-18-0565","article-title":"Molecular profiling for acromegaly treatment: a validation study","volume":"27","author":"Puig-Domingo","year":"2020","journal-title":"Endocr Relat Cancer"},{"issue":"6","key":"2026091519582375800_dgag241-B11","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1080\/17446651.2025.2561066","article-title":"Personalized medicine in acromegaly: insights from the ACROFAST clinical trial","volume":"20","author":"Araujo-Castro","year":"2025","journal-title":"Expert Rev Endocrinol Metab"},{"issue":"4","key":"2026091519582375800_dgag241-B12","doi-asserted-by":"crossref","first-page":"101893","DOI":"10.1016\/j.beem.2024.101893","article-title":"Predictors of biochemical response to somatostatin receptor ligands in acromegaly","volume":"38","author":"Marazuela","year":"2024","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"issue":"11","key":"2026091519582375800_dgag241-B13","doi-asserted-by":"crossref","first-page":"4973","DOI":"10.1210\/jc.2010-0573","article-title":"Magnetic resonance imaging as a predictor of response to somatostatin analogs in acromegaly after surgical failure","volume":"95","author":"Puig-Domingo","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"2026091519582375800_dgag241-B14","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1111\/cen.14946","article-title":"Magnetic resonance imaging as a predictor of therapeutic response to pasireotide in acromegaly","volume":"99","author":"Ruiz","year":"2023","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"3","key":"2026091519582375800_dgag241-B15","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1111\/cen.15177","article-title":"Correction to \u201cmagnetic resonance imaging as a predictor of therapeutic response to pasireotide in acromegaly\u201d","volume":"103","year":"2025","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2026091519582375800_dgag241-B16","doi-asserted-by":"crossref","first-page":"1269787","DOI":"10.3389\/fendo.2023.1269787","article-title":"Revisiting the usefulness of the short acute octreotide test to predict treatment outcomes in acromegaly","volume":"14","author":"Marques-Pamies","year":"2023","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"8","key":"2026091519582375800_dgag241-B17","doi-asserted-by":"crossref","first-page":"102924","DOI":"10.1016\/j.arcmed.2023.102924","article-title":"Predictors of response to treatment with first-generation somatostatin receptor ligands in patients with acromegaly","volume":"54","author":"Marques-Pamies","year":"2023","journal-title":"Arch Med Res"},{"issue":"1","key":"2026091519582375800_dgag241-B18","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1210\/clinem\/dgae444","article-title":"Personalized medicine in acromegaly: the ACROFAST study","volume":"110","author":"Marques-Pamies","year":"2024","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2026091519582375800_dgag241-B19","doi-asserted-by":"crossref","first-page":"e205","DOI":"10.1210\/clinem\/dgae665","article-title":"Correction to: \u201cpersonalized medicine in acromegaly: the ACROFAST study\u201d","volume":"110","year":"2024","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"2026091519582375800_dgag241-B20","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/s12020-015-0766-8","article-title":"Quantitative analyses of T2-weighted MRI as a potential marker for response to somatostatin analogs in newly diagnosed acromegaly","volume":"52","author":"Heck","year":"2016","journal-title":"Endocrine"},{"issue":"1","key":"2026091519582375800_dgag241-B21","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1111\/j.1365-2265.2011.04286.x","article-title":"Intensity of pituitary adenoma on T2-weighted magnetic resonance imaging predicts the response to octreotide treatment in newly diagnosed acromegaly","volume":"77","author":"Heck","year":"2012","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"11","key":"2026091519582375800_dgag241-B22","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1530\/ERC-16-0356","article-title":"T2-weighted MRI signal predicts hormone and tumor responses to somatostatin analogs in acromegaly","volume":"23","author":"Potorac","year":"2016","journal-title":"Endocr Relat Cancer"},{"issue":"12","key":"2026091519582375800_dgag241-B23","doi-asserted-by":"crossref","first-page":"3315","DOI":"10.3390\/biomedicines11123315","article-title":"Pathologic characteristics of somatotroph pituitary tumors-an observational single-center study","volume":"11","author":"Tomasik","year":"2023","journal-title":"Biomedicines"},{"key":"2026091519582375800_dgag241-B24","doi-asserted-by":"crossref","first-page":"957301","DOI":"10.3389\/fendo.2022.957301","article-title":"Clinical, hormonal and pathomorphological markers of somatotroph pituitary neuroendocrine tumors predicting the treatment outcome in acromegaly","volume":"13","author":"Tomasik","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"6","key":"2026091519582375800_dgag241-B25","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1007\/s11102-023-01353-0","article-title":"Clinical and prognostic significance of granulation patterns in somatotroph adenomas\/tumors of the pituitary: a meta-analysis","volume":"26","author":"Vuong","year":"2023","journal-title":"Pituitary"},{"issue":"1","key":"2026091519582375800_dgag241-B26","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1530\/eje.1.01935","article-title":"Limited predictive value of an acute test with subcutaneous octreotide for long-term IGF-I normalization with sandostatin LAR in acromegaly","volume":"153","author":"de Herder","year":"2005","journal-title":"Eur J Endocrinol"},{"issue":"6","key":"2026091519582375800_dgag241-B27","first-page":"2356","article-title":"Prediction of efficacy of octreotide therapy in patients with acromegaly","volume":"81","author":"Colao","year":"1996","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"2026091519582375800_dgag241-B28","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1111\/j.1365-2265.2005.02278.x","article-title":"The nadir growth hormone after an octreotide test dose predicts the long-term efficacy of somatostatin analogue therapy in acromegaly","volume":"62","author":"Gilbert","year":"2005","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"6","key":"2026091519582375800_dgag241-B29","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1055\/s-2008-1065339","article-title":"A short acute octreotide test for response prediction of long-term treatment with somatostatin analogues in acromegalic patients","volume":"40","author":"Halperin","year":"2008","journal-title":"Horm Metab Res"},{"issue":"9","key":"2026091519582375800_dgag241-B30","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1507\/endocrj.EJ16-0175","article-title":"The value of an acute octreotide suppression test in predicting short-term efficacy of somatostatin analogues in acromegaly","volume":"63","author":"Wang","year":"2016","journal-title":"Endocr J"},{"issue":"5","key":"2026091519582375800_dgag241-B31","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1111\/cen.14339","article-title":"Molecular determinants of enhanced response to somatostatin receptor ligands after debulking in large GH-producing adenomas","volume":"94","author":"Gil","year":"2021","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"1","key":"2026091519582375800_dgag241-B32","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1210\/jc.2005-1208","article-title":"Partial surgical removal of growth hormone-secreting pituitary tumors enhances the response to somatostatin analogs in acromegaly","volume":"91","author":"Colao","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"2026091519582375800_dgag241-B33","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1111\/j.1365-2265.2007.03139.x","article-title":"Surgical debulking of pituitary macroadenomas causing acromegaly improves control by lanreotide","volume":"68","author":"Karavitaki","year":"2008","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"2","key":"2026091519582375800_dgag241-B34","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1530\/EJE-15-0832","article-title":"Factors predicting pasireotide responsiveness in somatotroph pituitary adenomas resistant to first-generation somatostatin analogues: an immunohistochemical study","volume":"174","author":"Iacovazzo","year":"2016","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"2026091519582375800_dgag241-B35","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s11102-024-01477-x","article-title":"Treatment of acromegaly-induced diabetes: an updated proposal","volume":"28","author":"Biagetti","year":"2024","journal-title":"Pituitary"},{"issue":"7","key":"2026091519582375800_dgag241-B36","doi-asserted-by":"crossref","DOI":"10.1530\/EC-25-0103","article-title":"Predictors of therapeutic failure in GH and prolactin co-secreting pituitary adenomas","volume":"14","author":"Araujo-Castro","year":"2025","journal-title":"Endocr Connect"},{"issue":"5","key":"2026091519582375800_dgag241-B37","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1210\/clinem\/dgaf634","article-title":"Clinical and pathological spectrum of acromegaly: distinguishing GH-PitNETs, mammosomatotrophs and mixed tumors","volume":"111","author":"Mart\u00ednez-Hern\u00e1ndez","year":"2026","journal-title":"J Clin Endocrinol Metab"},{"issue":"9","key":"2026091519582375800_dgag241-B38","doi-asserted-by":"crossref","DOI":"10.1210\/jendso\/bvac114","article-title":"Preoperative medical treatment for patients with acromegaly: yes or no?","volume":"6","author":"Albarel","year":"2022","journal-title":"J Endocr Soc"},{"issue":"4","key":"2026091519582375800_dgag241-B39","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0061523","article-title":"Place of preoperative treatment of acromegaly with somatostatin analog on surgical outcome: a systematic review and meta-analysis","volume":"8","author":"Pita-Gutierrez","year":"2013","journal-title":"PLoS One"},{"issue":"4","key":"2026091519582375800_dgag241-B40","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1093\/ejendo\/lvaf194","article-title":"Long-term antitumour effects of pasireotide in acromegaly","volume":"193","author":"van der Groef","year":"2025","journal-title":"Eur J Endocrinol"},{"key":"2026091519582375800_dgag241-B41","doi-asserted-by":"publisher","DOI":"10.1007\/s11154-024-09935-4","article-title":"Correction: real-world evidence of effectiveness and safety of pasireotide in the treatment of acromegaly: a systematic review and meta-analysis","author":"Biagetti","journal-title":"Rev Endocr Metab Disord"},{"issue":"1","key":"2026091519582375800_dgag241-B42","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/s11154-024-09928-3","article-title":"Real-world evidence of effectiveness and safety of pasireotide in the treatment of acromegaly: a systematic review and meta-analysis","volume":"26","author":"Biagetti","year":"2025","journal-title":"Rev Endocr Metab Disord"},{"issue":"2","key":"2026091519582375800_dgag241-B43","doi-asserted-by":"crossref","first-page":"169","DOI":"10.23736\/S0391-1977.18.02937-1","article-title":"Precision medicine in the treatment of acromegaly","volume":"44","author":"Puig-Domingo","year":"2019","journal-title":"Minerva Endocrinol"},{"issue":"3","key":"2026091519582375800_dgag241-B44","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/S2213-8587(23)00382-0","article-title":"A proposed clinical classification for pituitary neoplasms to guide therapy and prognosis","volume":"12","author":"Ho","year":"2024","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"12","key":"2026091519582375800_dgag241-B45","doi-asserted-by":"crossref","first-page":"3391","DOI":"10.1210\/clinem\/dgaf252","article-title":"Validation and limitations of the PANOMEN-3 predictive model for tumor recurrence and progression in pituitary tumors","volume":"110","author":"Araujo-Castro","year":"2025","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2026091519582375800_dgag241-B46","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1210\/jc.2014-2468","article-title":"A structural and functional acromegaly classification","volume":"100","author":"Cuevas-Ramos","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"2026091519582375800_dgag241-B47","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1530\/EJE-21-0239","article-title":"More than a decade of real-world experience of pegvisomant for acromegaly: ACROSTUDY","volume":"185","author":"Fleseriu","year":"2021","journal-title":"Eur J Endocrinol"},{"issue":"9","key":"2026091519582375800_dgag241-B48","doi-asserted-by":"crossref","first-page":"e3236","DOI":"10.1210\/clinem\/dgaa444","article-title":"Cost-effectiveness and efficacy of a novel combination regimen in acromegaly: a prospective, randomized trial","volume":"105","author":"Bonert","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"2026091519582375800_dgag241-B49","doi-asserted-by":"crossref","DOI":"10.1210\/jendso\/bvag030","article-title":"Cost-effectiveness of personalized medical treatment in acromegaly: a post hoc analysis of the ACROFAST study","volume":"10","author":"Marques-Pamies","year":"2026","journal-title":"J Endocr Soc"},{"issue":"6","key":"2026091519582375800_dgag241-B50","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1530\/EJE-19-0840","article-title":"T2-signal intensity, SSTR expression, and somatostatin analogs efficacy predict response to pasireotide in acromegaly","volume":"182","author":"Coopmans","year":"2020","journal-title":"Eur J Endocrinol"},{"key":"2026091519582375800_dgag241-B51","doi-asserted-by":"crossref","first-page":"648411","DOI":"10.3389\/fendo.2021.648411","article-title":"Pasireotide in the personalized treatment of acromegaly","volume":"12","author":"Puig-Domingo","year":"2021","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"4","key":"2026091519582375800_dgag241-B52","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1210\/jc.2003-031344","article-title":"The novel somatostatin analog SOM230 is a potent inhibitor of hormone release by growth hormone- and prolactin-secreting pituitary adenomas in vitro","volume":"89","author":"Hofland","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"issue":"7","key":"2026091519582375800_dgag241-B53","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1210\/clinem\/dgab125","article-title":"Machine learning-based prediction model for treatment of acromegaly with first-generation somatostatin receptor ligands","volume":"106","author":"Wildemberg","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2026091519582375800_dgag241-B54","doi-asserted-by":"crossref","first-page":"8979","DOI":"10.1038\/s41598-022-12955-2","article-title":"Data mining analyses for precision medicine in acromegaly: a proof of concept","volume":"12","author":"Gil","year":"2022","journal-title":"Sci Rep"},{"issue":"2","key":"2026091519582375800_dgag241-B55","doi-asserted-by":"crossref","first-page":"R1","DOI":"10.1093\/ejendo\/lvaf144","article-title":"Multimodal advanced imaging for precision medicine in pituitary tumors","volume":"193","author":"Hanzu","year":"2025","journal-title":"Eur J Endocrinol"},{"issue":"3","key":"2026091519582375800_dgag241-B56","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1210\/jc.2015-3653","article-title":"Pituitary medicine from discovery to patient-focused outcomes","volume":"101","author":"Melmed","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"issue":"11","key":"2026091519582375800_dgag241-B57","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1038\/s41574-023-00883-8","article-title":"Pituitary adenoma or neuroendocrine tumour: the need for an integrated prognostic classification","volume":"19","author":"Ho","year":"2023","journal-title":"Nat Rev Endocrinol"}],"container-title":["The Journal of Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jcem\/advance-article-pdf\/doi\/10.1210\/clinem\/dgag241\/68550131\/dgag241.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/111\/10\/2969\/68550131\/dgag241.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/111\/10\/2969\/68550131\/dgag241.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T23:58:34Z","timestamp":1789516714000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/111\/10\/2969\/8711125"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,18]]},"references-count":57,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2026,6,18]]},"published-print":{"date-parts":[[2026,9,16]]}},"URL":"https:\/\/doi.org\/10.1210\/clinem\/dgag241","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,10]]},"published":{"date-parts":[[2026,6,18]]}}}